Loading

0%

Cardiovascular,
Renal &
Metabolism

Targeting core disease mechanisms
to address underserved CVRM conditions

We are strategically positioned to derisk the best breakthrough therapeutic programs from Europe’s top academic research centers and accelerate them toward clinical development.

Latest News

October 29, 2024

AndzonBio1 raises initial €3M in seed funding to advance breakthrough treatments for Cardiovascular, Renal and Metabolic Disorders

AndzonBio1, the first thematic studio of the AndzonBio® initiative, has raised an initial €3M ($3.28M) in seed funding from AdBio Partners...

Read more

June 18, 2024

Inserm Transfert and AdBio partners launch AndzonBio®

AdBio partners, a leading European early stage Venture Capital firm dedicated to life sciences, and Inserm Transfert, the private company, subsidiary of the French National Institute of Health and Medical Research (Inserm) Europe's leading player in life sciences research, are strengthening their strategic alliance and are announcing the launch of a suite of thematic Biotech Venture Studios: AndzonBio...

Read more
 
follow us on LinkedInFollow us on LinkedIn

Contact

10, rue d’Oradour-sur-Glane
75015 Paris

Contact us for any questions:

contact@andzonbio1.comcontact@andzonbio1.com